WO2018181774A1 - 新規モノオキシゲナーゼおよびその利用 - Google Patents
新規モノオキシゲナーゼおよびその利用 Download PDFInfo
- Publication number
- WO2018181774A1 WO2018181774A1 PCT/JP2018/013363 JP2018013363W WO2018181774A1 WO 2018181774 A1 WO2018181774 A1 WO 2018181774A1 JP 2018013363 W JP2018013363 W JP 2018013363W WO 2018181774 A1 WO2018181774 A1 WO 2018181774A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- amino acid
- acid sequence
- seq
- monooxygenase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/04—Alpha- or beta- amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
- C12N9/0083—Miscellaneous (1.14.99)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0095—Oxidoreductases (1.) acting on iron-sulfur proteins as donor (1.18)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
Definitions
- the present invention relates to a novel monooxygenase, a gene encoding the same, and use thereof.
- Optically active ⁇ , ⁇ -2 substituted amino acids are expected as building blocks for peptide drugs in order to increase the stability against peptidases (Non-patent Document 1).
- Non-Patent Document 2 discloses the production of an optically active ⁇ , ⁇ -2 substituted amino acid by an asymmetric alkylation reaction using an asymmetric phase transfer catalyst. A method is described. Patent Document 1 describes a reaction for synthesizing ⁇ -methyl-L-serine by an enzymatic reaction using L-alanine and formaldehyde as raw materials.
- Non-Patent Document 2 provides an optically active ⁇ , ⁇ -2-substituted amino acid, there is a problem that complicated steps such as introduction of a protecting group and a deprotection step after the reaction are required.
- the method of Patent Document 1 is a production method that does not require a protecting group, only L-form ⁇ -methyl-L-serine can be synthesized, and its optical isomer ⁇ -methyl-D-serine is synthesized. I can't do it.
- an object of the present invention is to provide a novel enzyme protein that enables the production of ⁇ -hydroxyamino acids containing optically active ⁇ , ⁇ -2 substituted amino acids, such as ⁇ -methyl-D-serine.
- the present inventor has found and isolated a microorganism having the ability to convert 2-aminoisobutyric acid into optically active ⁇ -methyl-D-serine in nature. succeeded in. Furthermore, a novel monooxygenase that converts 2-aminoisobutyric acid to ⁇ -methyl-D-serine was successfully identified by proteomic analysis of the above microorganisms and various analyzes related thereto.
- one embodiment of the present invention includes the following inventions.
- a monooxygenase comprising two types of hetero subunits.
- the ⁇ subunit comprises any protein selected from the group consisting of the following (a) to (d): The monooxygenase according to any one of [1] to [4], wherein the ⁇ subunit includes any protein selected from the group consisting of the following (e) to (h): (A) a protein comprising the amino acid sequence set forth in SEQ ID NO: 1; (B) a protein comprising an amino acid sequence in which one or several amino acid residues are substituted, deleted, inserted and / or added in the amino acid sequence shown in SEQ ID NO: 1, and a subunit containing the protein A protein having monooxygenase activity when complexed with the ⁇ subunit; (C) a monooxygenase which is a protein comprising an amino acid sequence having 80% or more homology with the amino acid sequence described in SEQ ID NO: 1 and a subunit containing the protein forms a complex with a ⁇
- a monooxygenase reaction system for producing a ⁇ -hydroxyamino acid comprising the monooxygenase according to any one of [1] to [5] and an electron transfer protein.
- the electron transfer protein is any protein selected from the group consisting of the following (i) to (l), and any one selected from the group consisting of the following (m) to (p):
- the monooxygenase reaction system according to [6] which is a protein of: (I) a protein comprising the amino acid sequence set forth in SEQ ID NO: 3; (J)
- the amino acid sequence shown in SEQ ID NO: 3 consists of an amino acid sequence in which one or several amino acid residues are substituted, deleted, inserted and / or added, and the following (m) to (p A protein having electron transfer activity when combined with any protein selected from the group consisting of:
- a transformant comprising the gene according to [8] or the recombinant vector according to [9].
- the transformant according to [10] which contains the gene shown below: (1) a gene encoding an electron transport system protein, and / or (2) a gene encoding a transporter protein.
- the electron transfer system protein is any protein selected from the group consisting of the following (i) to (l), and any one selected from the group consisting of the following (m) to (p):
- the amino acid sequence shown in SEQ ID NO: 3 consists of an amino acid sequence in which one or several amino acid residues are substituted, deleted, inserted and / or added, and the following (m) to (p A protein having electron transfer activity when combined with any protein selected from the group consisting of: (K) A combination with any protein selected from the group consisting of the following (m) to (p) consisting of an amino acid sequence having 80% or more homology with the amino acid sequence shown in SEQ ID NO: 3
- the transporter protein is any protein selected from the group consisting of the following (q) to (t): : (Q) a protein comprising the amino acid sequence set forth in SEQ ID NO: 5; (R) a protein having a transporter activity consisting of an amino acid sequence in which one or several amino acid residues are substituted, deleted, inserted and / or added in the amino acid sequence shown in SEQ ID NO: 5; (S) a protein comprising an amino acid sequence having 80% or more homology with the amino acid sequence described in SEQ ID NO: 5 and having transporter activity; (T) A protein encoded by a gene consisting of the base sequence set forth in SEQ ID NO: 10.
- [15] A step of culturing the transformant according to any one of [10] to [14] in a medium containing an ⁇ -amino acid or an ⁇ , ⁇ -2 substituted amino acid, A method for producing a hydroxyamino acid.
- Rhodococcus latislaviensis C31-06 strain (Accession number: NITE BP-02370).
- an ⁇ -amino acid or ⁇ , ⁇ -2 substituted amino acid can be converted into a ⁇ -hydroxyamino acid simply and efficiently without the need for introducing a protecting group or a deprotecting step. it can.
- the term “gene” is used interchangeably with “polynucleotide”, “nucleic acid” or “nucleic acid molecule” and is intended to be a polymer of nucleotides.
- the gene may be present in the form of DNA (eg, cDNA or genomic DNA) or RNA (eg, mRNA).
- DNA or RNA may be double-stranded or single-stranded.
- Single-stranded DNA or RNA may be a coding strand (sense strand) or a non-coding strand (antisense strand).
- the gene may be chemically synthesized, and the codon usage may be changed so that the expression of the encoded protein is improved. Substitutions can be made between codons encoding the same amino acid.
- protein is used interchangeably with “peptide” or “polypeptide”.
- polypeptide or “polypeptide”.
- base and amino acid notation uses the one-letter code or three-letter code defined by IUPAC and IUB as appropriate.
- Monooxygenase composed of at least two types of hetero (different) subunits (in other words, a heteromonooxygenase composed of two or more different subunits).
- Monooxygenase is a kind of oxidase and is an enzyme that introduces one oxygen atom into a substrate.
- Most known monooxygenases function as a single enzyme from the viewpoint of structure, and are constituted by a complex (heterosubunit) as in one embodiment of the present invention.
- Monooxygenase was not known. Therefore, the discovery of the monooxygenase in one embodiment of the present invention having the above structure is surprising, and it becomes possible to catalyze reactions that are impossible or low in reactivity with conventional monooxygenases. Therefore, in one embodiment of the present invention, a novel and useful monooxygenase that has not been heretofore provided is provided.
- the monooxygenase in one embodiment of the present invention is preferably composed of two types of hetero (different) subunits.
- the number of subunits is not particularly limited as long as it has monooxygenase activity when complexed with other subunits, and may be, for example, 2, 3, 4, 5, etc.
- each subunit of monooxygenase in one embodiment of the present invention is not particularly limited as long as it has monooxygenase activity when complexed with other subunits, such as monomers, dimers, trimers, tetramers, etc. It may be comprised.
- the monooxygenase in one embodiment of the present invention is composed of a heterodimer, heterotrimer, heterotetramer, heteropentamer, heterohexamer and the like containing the above subunits as long as monooxygenase activity occurs. May be.
- monooxygenase in one embodiment of the present invention has the characteristic configuration shown above, the details thereof can be appropriately changed. Of course, monooxygenases with such details modified are also within the scope of the present invention.
- the origin of monooxygenase in one embodiment of the present invention is a fungus, for example, actinomycetes, and examples thereof include the genus Rhodococcus and the genus Nocardia.
- the monooxygenase is Rhodococcus erythropolis, Rhodococcus rhodochrous, and preferably Rhodococcus rastropis. (Rhodococcus wratislaviensis).
- Rhodococcus wratislaviensis C31-06 strain The monooxygenase in one embodiment of the present invention was obtained from Rhodococcus wratislaviensis C31-06 strain, as shown in Examples described later.
- Rhodococcus rhitoclaviensis C31-06 strain is incorporated into the National Institute of Technology and Evaluation (NITE) Patent Microorganisms Deposit Center (292-0818, 2-10-8 Kazusa Kamashika, Kisarazu City, Chiba Prefecture) Depositary: National University Corporation graduate School of Agriculture, Kyoto University Shingo Hibashi (606-8502 Kitashirakawa Oiwakecho, Sakyo-ku, Kyoto, Kyoto), Deposit Number: NITE BP-02370 (Deposit Date (Domestic Deposit Date): October 2016 6th, transfer date: Deposited as of March 12, 2018 under the domestic deposit number NITE P-02370). Therefore, the present invention also provides the Rhodococcus wratislaviensis C31-06 strain.
- the monooxygenase in one embodiment of the present invention can catalyze the reaction of converting an ⁇ -amino acid or ⁇ , ⁇ -2 substituted amino acid into an optically active ⁇ -hydroxyamino acid. That is, monooxygenase capable of catalyzing the reaction of converting ⁇ -amino acid or ⁇ , ⁇ -2 substituted amino acid to optically active ⁇ -hydroxyamino acid, preferably ⁇ -amino acid or ⁇ , ⁇ -2 substituted amino acid
- a monooxygenase from the genus Rhodococcus that can catalyze the reaction of converting to an active ⁇ -hydroxy amino acid is another preferred embodiment of the present invention.
- ⁇ -amino acid means an amino acid in which the ⁇ position of the amino acid is monosubstituted.
- examples of the ⁇ -amino acid in the present embodiment include, but are not limited to, L-aminobutyrate, D-aminobutyrate, and the like.
- ⁇ , ⁇ -2 substituted amino acid means an amino acid in which the ⁇ position of the amino acid is disubstituted.
- Examples of ⁇ , ⁇ -2 substituted amino acids in the present embodiment include, but are not limited to, 2-aminoisobutyric acid, L-isovaline, D-isovaline and the like.
- ⁇ -hydroxy amino acid means an amino acid in which the ⁇ -position of an amino acid is hydroxylated, such as ⁇ -amino acid, ⁇ , ⁇ -2 substituted amino acid, etc. by monooxygenase in one embodiment of the present invention.
- the substrate is not particularly limited as long as it is an amino acid that has optical activity.
- the ⁇ -hydroxyamino acid in this embodiment include ⁇ -methyl-D-serine, (2S, 3S) -2-methylthreonine, (2R, 3R) -2-methylthreonine, L-allo-threonine, D -Allo-threonine and the like.
- the term “optically active ⁇ -hydroxyamino acid” is used synonymously with “ ⁇ -hydroxyamino acid”.
- the monooxygenase in one embodiment of the present invention is assumed to be converted to a ⁇ -hydroxyamino acid by catalyzing hydroxylation at the ⁇ -position of ⁇ -amino acid or ⁇ , ⁇ -2 substituted amino acid.
- Any ⁇ -amino acid, ⁇ , ⁇ -2 substituted amino acid, and ⁇ -hydroxy amino acid may be used as long as they can be converted into optically active ⁇ -hydroxy amino acids by the above monooxygenase. It's okay.
- the ⁇ -amino acid or ⁇ , ⁇ -2 substituted amino acid that is converted to ⁇ -hydroxyamino acid by monooxygenase is preferably a compound represented by the following formula (1):
- R 1 and R 2 are each independently hydrogen or an alkyl group.
- R 1 is an alkyl group
- the carbon number thereof may be 1 to 5, preferably 1 to 3, and more preferably 1.
- the alkyl group may be linear, branched, or cyclic, and preferably may be linear.
- R 2 is an alkyl group, it is the same as R 1 above.
- * may or may not be an asymmetric carbon atom.
- the ⁇ -hydroxyamino acid converted from ⁇ -amino acid or ⁇ , ⁇ -2 substituted amino acid by monooxygenase is preferably a compound represented by the following formula (2): :
- R 3 and R 4 are each independently hydrogen or an alkyl group.
- R 3 is an alkyl group
- the carbon number thereof may be 1 to 5, preferably 1 to 3, and more preferably 1.
- the alkyl group may be linear, branched, or cyclic, and preferably may be linear.
- R 4 is an alkyl group, it is the same as R 3 above.
- * may or may not be an asymmetric carbon atom, and preferably either * or more preferably * may be an asymmetric carbon atom.
- At least one or more of reactions for converting an ⁇ -amino acid or ⁇ , ⁇ -2 substituted amino acid into an optically active ⁇ -hydroxy amino acid represented by the following formulas (3) to (7): Monooxygenases that catalyze the reaction of are preferred: Formula (3) Formula (4) Formula (5) Formula (6) Formula (7)
- the monooxygenase according to one embodiment of the present invention is an optical form of a ⁇ -hydroxy amino acid obtained in the reaction of converting an ⁇ -amino acid or ⁇ , ⁇ -2 substituted amino acid into an optically active ⁇ -hydroxy amino acid represented by the above formula. It is preferable that the purity can be converted to 60% or higher, more preferably 80% or higher, and more preferably 85% or higher. Is more preferable, and it is particularly preferable that the conversion is 87% or more.
- the monooxygenase according to one embodiment of the present invention is such that when the two types of hetero subunits are ⁇ subunit and ⁇ subunit, respectively, the ⁇ subunit is selected from the group consisting of the following (a) to (d):
- the ⁇ subunit comprises any protein selected from the group consisting of the following (e) to (h): (A) a protein comprising the amino acid sequence set forth in SEQ ID NO: 1; (B) a protein comprising an amino acid sequence in which one or several amino acid residues are substituted, deleted, inserted and / or added in the amino acid sequence shown in SEQ ID NO: 1, and a subunit containing the protein A protein having monooxygenase activity when complexed with the ⁇ subunit; (C) a monooxygenase which is a protein comprising an amino acid sequence having 80% or more homology with the amino acid sequence described in SEQ ID NO: 1 and a subunit containing the protein forms a complex with a ⁇ subunit An active
- the proteins (a) and (e) above are proteins consisting of the amino acid sequences shown in SEQ ID NOs: 1 and 2, both of which are derived from Rhodococcus bratislaviensis.
- SEQ ID NO: 1 is a polypeptide composed of a full length 378 mino acid residue, and Protein ID is peg. In Protein Discover Software (Thermo Scientific). It is labeled 803.
- SEQ ID NO: 2 is a polypeptide composed of 373 amino acid residues in total length, and Protein ID is peg. In Protein Discover Software (Thermo Scientific). Labeled as 804.
- the above proteins (b) and (f) are functionally equivalent mutants, derivatives, variants, alleles, homologs, orthologs, partial peptides, or others of the proteins having the amino acid sequences shown in SEQ ID NOs: 1 and 2.
- a subunit containing the protein has a monooxygenase activity when it forms a complex with the ⁇ subunit
- the specific sequence is not limited as long as the subunit containing the protein has a monooxygenase activity when complexed with the ⁇ subunit.
- the number of amino acids that may be deleted, substituted or added is not limited as long as the above function is not lost.
- the number of amino acids may be deleted, substituted or deleted by a known introduction method such as site-directed mutagenesis.
- the number is such that it can be added, preferably within 5 amino acids, more preferably within 3 amino acids (eg, 3, 2 or 1 amino acid).
- “mutation” mainly means a mutation artificially introduced by site-directed mutagenesis or the like, but may be a naturally occurring similar mutation.
- amino acid residue to be substituted is preferably substituted with another amino acid that preserves the properties of the amino acid side chain.
- amino acid side chain properties include hydrophobic amino acids (A, I, L, M, F, P, W, Y, V), hydrophilic amino acids (R, D, N, C, E, Q, G).
- an amino acid having an aliphatic side chain G, A, V, L, I, P
- an amino acid having a hydroxyl group-containing side chain S, T, Y
- Amino acids having chains C, M
- amino acids having carboxylic acid and amide-containing side chains D, N, E, Q
- amino acids having base-containing side chains R, K, H
- aromatic-containing side chains H, F, Y, W
- “functionally equivalent” means that the target protein has a biological function or biochemical function equivalent (same and / or similar) to the target protein.
- Biological properties may include the specificity of the site to be expressed, the expression level, and the like. Whether or not a protein into which a mutation has been introduced has a desired function can be determined by examining whether or not the protein has monooxygenase activity when the protein is used as a part of a subunit.
- the above proteins (c) and (g) are also functionally equivalent mutants, derivatives, variants, alleles, homologs, orthologs, partial peptides, or others of the proteins having the amino acid sequences shown in SEQ ID NOs: 1 and 2.
- the protein (c) as long as the subunit containing the protein has a monooxygenase activity when it forms a complex with the ⁇ subunit.
- the specific sequence is not limited as long as the subunit containing the protein has a monooxygenase activity when complexed with the ⁇ subunit.
- Amino acid sequence homology is at least 80% or more, preferably 85% or more, more preferably 90% or more, even more preferably 95% or more (for example, 95%) in the entire amino acid sequence (or a region necessary for functional expression). %, 96%, 97%, 98%, 99% or more).
- Amino acid sequence homology can be determined using BLASTN (nucleic acid level) and BLASTX (amino acid level) programs (Altschul et al. J. Mol. Biol., 215: 403-410, 1990). The program is based on the algorithm BLAST by Karlin and Altschul (Proc. Natl. Acad. Sci. USA, 87: 2264-2268, 1990, Proc. Natl. Acad.
- homology intends the ratio of the number of amino acid residues having similar properties (homology, positive, etc.), but more preferably the ratio of the number of identical amino acid residues, ie, identity. (Identity).
- the properties of amino acids are as described above.
- SEQ ID NOs: 6 and 7 show the base sequences (Open Reading Frame: ORF) of the genes encoding the proteins consisting of the amino acid sequences shown by SEQ ID NOS: 1 and 2, respectively.
- a commonly used method for modifying a polynucleotide may be used. That is, a polynucleotide having the genetic information of a desired recombinant protein can be produced by substituting, deleting, inserting and / or adding a specific base of the polynucleotide having the genetic information of the protein.
- Specific methods for converting the bases of the polynucleotide include, for example, commercially available kits (KOD-Plus Site-Directed Mutagenesis Kit (Toyobo), Transformer Site-Directed Mutagenesis Kit (Clontech), QuickChangeSiteMititeDigit ) Or use of the polymerase chain reaction (PCR). These methods are known to those skilled in the art.
- the gene may be composed only of a polynucleotide encoding the protein, but other base sequences may be added.
- the base sequence to be added is not particularly limited, but includes a label (for example, histidine tag, Myc tag or FLAG tag), a fusion protein (for example, streptavidin, cytochrome, GST, GFP or MBP), a promoter sequence, and Examples thereof include a base sequence encoding a signal sequence (for example, an endoplasmic reticulum transition signal sequence, a secretory sequence, etc.).
- the site to which these base sequences are added is not particularly limited and may be, for example, the N-terminus or C-terminus of the translated protein.
- Monooxygenase reaction system for producing a ⁇ -hydroxyamino acid comprising the above monooxygenase and an electron transfer system protein.
- the present monooxygenase reaction system is a system in which the monooxygenase produces ⁇ -hydroxyamino acid by supplying redox power via an electron transfer system protein, and includes the monooxygenase and an electron transfer system protein. As long as the system can produce ⁇ -hydroxyamino acid, it is not particularly limited.
- the present monooxygenase reaction system may be a system constructed in a living organism or an artificially constructed system outside a living organism.
- the monooxygenase reaction system is preferably a system constructed in an organism from the viewpoint of the stability and activity of the monooxygenase protein.
- the construction of the present monooxygenase reaction system in the organism may be that the organism originally has the system, or artificially introduce the system into an organism that does not have the system. Good.
- the method for artificially introducing the present monooxygenase reaction system and the target of introduction are not particularly limited.
- Vector> and ⁇ 5. It can be carried out by the method described in the section ⁇ Transformant>.
- the electron transfer protein in the monooxygenase reaction system is not particularly limited as long as it is a protein that supplies the redox power for the monooxygenase to generate monooxygenase activity.
- Examples of the electron transfer system protein include a combination of ferredoxin and ferredoxin reductase (ferredoxin is, for example, liske protein, putidaredoxin, adrenodoxin, etc., and ferredoxin reductase is, for example, flavoprotein reductase, putidaredoxin reductase, And a combination of flavodoxin and flavodoxin reductase, P450 reductase, and the like.
- ferredoxin is, for example, liske protein, putidaredoxin, adrenodoxin, etc.
- ferredoxin reductase is, for example, flavoprotein reductase, putidaredoxin reductase, And a combination of flavodoxin and flavodoxin reductase, P450 reductase, and the like.
- the electron transfer system protein is selected from any one protein selected from the group consisting of the following (i) to (l), and from the group consisting of the following (m) to (p):
- any of the proteins that are: (I) a protein comprising the amino acid sequence set forth in SEQ ID NO: 3; (J)
- the amino acid sequence shown in SEQ ID NO: 3 consists of an amino acid sequence in which one or several amino acid residues are substituted, deleted, inserted and / or added, and the following (m) to (p A protein having electron transfer activity when combined with any protein selected from the group consisting of:
- the proteins (i) and (m) above are proteins consisting of the amino acid sequences shown in SEQ ID NOs: 3 and 4, both of which are derived from Rhodococcus bratislaviensis.
- SEQ ID NO: 3 is a polypeptide composed of a full-length 322 mino acid residue.
- SEQ ID NO: 4 is a polypeptide composed of a full-length 169 mino acid residue. In Protein Discover Software (Thermo Scientific), the Protein ID is peg. Labeled as 802.
- the proteins (j) and (n) above are functionally equivalent mutants, derivatives, variants, alleles, homologs, orthologs, partial peptides, or others of the proteins having the amino acid sequences shown in SEQ ID NOs: 3 and 4.
- a protein (j) such as a fusion protein with a protein or peptide of (j)
- the electron transfer activity is exhibited when combined with any protein selected from the group consisting of (m) to (p)
- the protein of (n) its specific sequence as long as it has electron transfer activity when combined with any protein selected from the group consisting of (i) to (l) Is not limited.
- the above proteins (k) and (o) are also functionally equivalent mutants, derivatives, variants, alleles, homologs, orthologs, partial peptides, or others of the proteins having the amino acid sequences shown in SEQ ID NOs: 3 and 4.
- the protein (k) electron transfer when combined with any protein selected from the group consisting of (m) to (p)
- the specific examples thereof are as long as it has electron transfer activity when combined with any protein selected from the group consisting of (i) to (l).
- SEQ ID NOs: 8 and 9 represent the base sequences (Open Reading Frame: ORF) of the genes encoding the proteins consisting of the amino acid sequences shown by SEQ ID NOs: 3 and 4, respectively.
- the electron transfer protein is limited to a protein selected from the group consisting of (i) to (l) and a protein selected from the group consisting of (m) to (p). It is intended that other proteins involved in the electron transport system may be included.
- a monooxygenase gene encoding the protein is provided.
- the protein is ⁇ 1. It may be a protein constituting the monooxygenase in one embodiment of the present invention described in the section “Monooxygenase>”.
- Vector> In one embodiment of the invention, ⁇ 3.
- a vector comprising the gene described in the section ⁇ Gene> is provided. This vector includes not only an expression vector for expressing the above gene in a host cell for producing a transformant, but also a vector used for production of a recombinant protein.
- the base material vector serving as the base of the vector various commonly used vectors can be used.
- a plasmid, phage, cosmid or the like can be used, and can be appropriately selected according to the cell to be introduced or the introduction method. That is, the specific type of vector is not particularly limited, and a vector that can be expressed in a host cell may be appropriately selected.
- an appropriate promoter sequence may be selected to ensure that the gene is expressed, and a gene obtained by incorporating this gene and the gene into various plasmids may be used as an expression vector.
- Such expression vectors include, for example, phage vectors, plasmid vectors, viral vectors, retroviral vectors, chromosomal vectors, episomal vectors and virus-derived vectors (eg, bacterial plasmids, bacteriophages, yeast episomes, yeast chromosomal elements and viruses (eg, baculo Vectors derived from viruses, papovaviruses, vaccinia viruses, adenoviruses, tripox viruses, pseudorabies viruses, herpes viruses, lentiviruses and retroviruses)) and combinations thereof can be used.
- virus-derived vectors eg, bacterial plasmids, bacteriophages, yeast episomes, yeast chromosomal elements and viruses (eg, baculo Vectors derived from viruses, papovaviruses, vaccinia viruses, adenoviruses, tripox viruses, pseudorabies viruses, herpes viruses, lentiviruses and retroviruse
- pQE60, pQE70, pQE80 and pQE9 available from Qiagen
- pTipQC1 available from Qiagen or Hokkaido System Science
- pTipRT2 available from Hokkaido System Science
- pBS Vectors, Pagescript vector, Bluescript vector, pNH8A, pNH16A, pNH18A and pNH46A available from Stratagene
- ptrc99a, pKK223-3, pKK233-3, pDR540 and pRIT5 available from Addgene
- pRSF available from MERCK
- As well as pAC available from Nippon Gene Co., Ltd.
- Also preferred eukaryotic vectors include pWLNE0, pSV2CAT, pOG44, pXT1 and pSG (available from Stratagene); and pSVK3, pBPV, pMSG and pSVL (available from Addgene).
- the gene insert is operably linked to an appropriate promoter.
- suitable promoters may be those known to those skilled in the art, and are not particularly limited.
- the vector further includes a site for transcription initiation and transcription termination, and a ribosome binding site for translation in the transcription region.
- the coding portion of the mature transcript expressed by the vector construct will contain a transcription start AUG at the beginning of the polypeptide to be translated and a stop codon appropriately located at the end.
- the host into which the vector is introduced is not particularly limited, but various cells can be suitably used.
- suitable hosts include, but are not limited to, bacteria, yeasts, filamentous fungi, plant cells, animal cells and the like. Appropriate culture media and conditions for the above-described host cells can be used as known in the art.
- the method for introducing the vector into a host cell ie, the transformation method is not particularly limited, and the calcium phosphate method, liposome method, DEAE dextran method, microinjection method, cationic lipid-mediated transfection, electroporation, transduction Alternatively, a conventionally known method such as infection can be suitably used. Such methods are described in many standard laboratory manuals such as Davis et al., Basic Methods In Molecular Biology (1986).
- Transformant> In one embodiment of the invention, ⁇ 3. Genes described in the section “Gene> or ⁇ 4. A transformant comprising the recombinant vector described in the section ⁇ Vector> is provided.
- “including a gene or vector” means that it has been introduced into a target cell (host cell) so as to be expressed by a known genetic engineering technique (gene manipulation technique).
- the “transformant” means not only cells / tissues / organs but also individual organisms.
- production method As a production method (production method) of the present transformant, a method of transforming the above-described vector can be mentioned.
- the organism to be transformed is not particularly limited, and examples thereof include various organisms exemplified in the host cell.
- host cells used in one embodiment of the present invention include bacteria, yeasts, filamentous fungi, plant cells, animal cells and the like, but actinomycetes are preferred from the viewpoint of introduction and expression efficiency.
- Examples of the actinomycetes include bacteria belonging to the genus Rhodococcus and Nocardia, and preferably Rhodococcus erythropolis, Rhodococcus rhodocrose rhodococcus rhodosocros ), Nocardia globulara, etc. are used. As used in Examples described later, Rhodococcus erythropolis is particularly preferably used as the host cell.
- the transformant preferably further includes the following genes: (1) a gene encoding an electron transport system protein, and / or (2) a gene encoding a transporter protein.
- the electron transfer protein is not particularly limited.
- the protein may be an electron transfer system protein described in the section of monooxygenase reaction system>.
- the transporter protein is not particularly limited as long as it is a protein having a function of incorporating a substance serving as a substrate for the monooxygenase into the transformant.
- transporter protein examples include permease (eg, symporter, antiporter, uniporter, etc.), ABC transporter and the like.
- the transporter protein is preferably any protein selected from the group consisting of the following (q) to (t): (Q) a protein comprising the amino acid sequence set forth in SEQ ID NO: 5; (R) a protein having a transporter activity consisting of an amino acid sequence in which one or several amino acid residues are substituted, deleted, inserted and / or added in the amino acid sequence shown in SEQ ID NO: 5; (S) a protein comprising an amino acid sequence having 80% or more homology with the amino acid sequence described in SEQ ID NO: 5 and having transporter activity; (T) A protein encoded by a gene consisting of the base sequence set forth in SEQ ID NO: 10.
- the protein (q) is a protein having the amino acid sequence represented by SEQ ID NO: 5, and is derived from Rhodococcus bratislaviensis.
- SEQ ID NO: 5 is a polypeptide composed of a full-length 480 mino acid residue.
- the Protein ID is peg. Labeled 800.
- the protein of (r) above is a functionally equivalent variant, derivative, variant, allele, homolog, ortholog, partial peptide, or other protein / peptide of the protein having the amino acid sequence represented by SEQ ID NO: 5. As long as it is a fusion protein or the like and has transporter activity, its specific sequence is not limited.
- the protein of the above (s) is also a functionally equivalent variant, derivative, variant, allele, homolog, ortholog, partial peptide, or other protein / peptide of the protein having the amino acid sequence represented by SEQ ID NO: 5.
- the specific sequence is not limited as long as it is intended to be a fusion protein and has transporter activity.
- SEQ ID NO: 10 represents the base sequence (Open Reading Frame: ORF) of the gene encoding the protein consisting of the amino acid sequence shown in SEQ ID NO: 5, respectively.
- the transporter protein is not limited to a protein selected from the group consisting of the above (q) to (t), and other substances involved in substance transport (transport) on the cell membrane. It is intended that the protein may comprise:
- the gene encoding the electron transfer system protein is not included in the introduced host / transformant when it does not have an electron transfer system protein that supplies redox power to the monooxygenase. When it has an electron transfer protein that functions as a compensation and supplies the redox power to the monooxygenase, it can function as an enhancer of the supply of redox power.
- the transformant contains the gene encoding the transporter protein (2), the incorporation of the monooxygenase substrate into the transformant is promoted, and as a result, the production of ⁇ -hydroxyamino acid is efficiently performed. Has the advantage of being done.
- ⁇ 6 Process for producing ⁇ -hydroxyamino acid>
- ⁇ 5. There is provided a method for producing a ⁇ -hydroxyamino acid, comprising a step of culturing the transformant described in the section>Transformant> in a medium containing an ⁇ -amino acid or an ⁇ , ⁇ -2 substituted amino acid.
- the production of ⁇ -hydroxyamino acid in the present embodiment is ⁇ 5.
- the transformant described in the section “Transformant> may be used, and other specific configurations, conditions, materials, equipment used, and the like are not particularly limited.
- Actinomycetes are preferable as the transformant, and Rhodococcus erythropolis, particularly Rhodococcus erythropolis, is particularly preferable.
- Rhodococcus erythropolis particularly Rhodococcus erythropolis, is particularly preferable.
- ⁇ -hydroxyamino acids can be produced with high efficiency.
- the production of ⁇ -hydroxyamino acid by the transformant is established by the presence of the transformant and ⁇ -amino acid or ⁇ , ⁇ -2 substituted amino acid serving as a substrate in the medium at the same time.
- the addition timing of the ⁇ -amino acid or ⁇ , ⁇ -2 substituted amino acid to the medium is not particularly limited. For example, it is introduced simultaneously with the expression of the introduced gene in the transformant or in the transformant. Can be added either before or after expressing the expressed gene, or both.
- This embodiment may be a mode in which an ⁇ -amino acid or ⁇ , ⁇ -2 substituted amino acid is added to a medium that already contains a transformant. You may carry out by introduce
- the ⁇ -amino acid, ⁇ , ⁇ -2 substituted amino acid and ⁇ -hydroxyamino acid are ⁇ 1.
- Monooxygenase> can be used.
- a conventionally known technique can be suitably used as a method for culturing the host strain of the transformant, and there is no particular limitation.
- the temperature at the time of culture it is preferably 20 to 45 ° C., more preferably 25 to 35 ° C. according to a conventional method.
- the reaction time is not particularly limited, the culture is preferably performed for 1 to 120 hours, more preferably 24 to 72 hours after the transgene expression.
- the method for collecting ⁇ -hydroxyamino acid from the culture or bacterial cells can also be performed according to a method commonly used for obtaining a microbial product, and is not particularly limited.
- Example 1 Isolation of 2-aminoisobutyric acid-assimilating microorganism and evaluation of hydroxylation activity 0.1% 2-aminoisobutyric acid, 0.1% ammonium chloride, 0.1% potassium dihydrogen phosphate; 1% dipotassium hydrogen phosphate, 0.03% magnesium sulfate heptahydrate, 0.01% Difco Yeast Nitrogen Base w / o Amino Acids and Ammonium Sulfate, using 2 ml of liquid medium for accumulation, Each of the soil samples collected from was cultured with shaking at 28 ° C. for 5 days (all concentrations are shown in (w / v)% (hereinafter the same applies throughout the examples)).
- the culture medium in which the microorganisms had grown was inoculated into 2 ml of a new accumulation liquid medium. After repeating this operation several times, 2-aminoisobutyric acid assimilating microorganisms were isolated on a 1.5% agar plate medium prepared with the same components. Each of the isolated microorganisms was again inoculated into 2 ml of an accumulation liquid medium and cultured with shaking at 28 ° C. for 5 days. Thereafter, the wet cells collected by centrifugation at 8000 g for 10 minutes and washed twice with 0.85% saline were used for the following resting cell reaction.
- the resting cell reaction was performed by shaking 10 mM 2-aminoisobutyric acid, 10 mM glucose, 1 mM aminooxyacetic acid, 5% wet cells in 50 mM HEPES buffer (pH 7.5) at 300 rpm for 4 hours.
- Example 2 Proteome analysis of Wratislaviensis strain C31-06 Wratislaviensis strain C31-06 was added to 250 ml of 2-aminoisobutyric acid-induced liquid medium (0.1% 2-aminoisobutyric acid, 0.1% ammonium chloride, 0.1% potassium dihydrogen phosphate, 0.1% hydrogen phosphate 2 potassium, 0.03% magnesium sulfate heptahydrate, 0.01% Difco Yeast Nitrogen Base w / o Amino Acids and Ammonium Sulfate), or 250 ml of non-induced medium (2-aminoisobutyric acid-derived liquid medium). Using 0.05% glucose instead of 1% 2-aminoisobutyric acid), the cells were cultured at 28 ° C.
- Each cultured cell was collected by centrifugation at 4 ° C. and 8000 g for 10 minutes, and 7 M urea, 2.0 mM thiourea, 2% CHAPS, 10 mM dithiothreitol, 1 tablet / 10 ml protease inhibitor (Complete Mini, Roche). ) In 50 mM Tris-HCl (pH 8.0) buffer. 0.10 mm beads were added and the cells were crushed with a multi-bead shocker, and then centrifuged at 4 ° C. and 20000 g for 15 minutes. The obtained centrifugal supernatant was used as a cell lysate.
- the precipitate was washed with a minimum amount of 200 mM TEAB buffer (pH 8.0), combined with the cell lysate, and filtered through a 0.45 ⁇ m filter. The filtrate was then replaced using 200 mM TEAB buffer. To the substituted filtrate, 9.5 mM Tris (2-carbethyl) phosphine was added and treated at 55 ° C. for 60 minutes. Thereafter, iodoacetamide was added to 17.9 mM and treated at room temperature for 30 minutes. Finally, 2 to 4 times the amount of cold acetone was added and treated at ⁇ 20 ° C. for 3 hours. Proteins were recovered by centrifugation at 13000 g for 10 minutes at 4 ° C. Residual acetone was removed by treatment at 37 ° C. for 2 minutes.
- trypsin digestion of the protein was performed. Specifically, the collected protein was suspended in 200 mM TEAB buffer, and then digested with 47.6 ng / ⁇ l trypsin at 37 ° C. overnight. Thereafter, the obtained digest was labeled in 41 ⁇ l of acetonitrile using a tandem mass tag (TMT) 6-plex labeling kit (Thermo Fisher Scientific). After 60 minutes of reaction at room temperature, 8 ⁇ l of 5% hydroxylamine was added and mixed for 15 minutes. The liquid was then evaporated under vacuum and then dissolved in 100 ⁇ l of 0.1% trifluoroacetic acid.
- TMT tandem mass tag 6-plex labeling kit
- the trypsin-digested protein obtained as described above was subjected to LCMS analysis (Prominence Nano Flow System (Shimadzu Corporation)).
- the obtained mass spectrometry data and R.I. Induced proteins were identified using Protein Discover Software (Thermo Scientific) equipped with a protein database created based on genome information of Wratislaviensis strain C31-06 (obtained by Hokkaido System Science). The results are shown in Table 2.
- PCR is performed under the following PCR conditions, and peg.
- a PCR product of 801-804 was obtained.
- the PCR product was inserted into a vector pTipQC1 (Hokkaido System Science) treated with NcoI and HindIII with NEBuilder HiFi DNA Assembly Master Mix (NewngEngland BioLabs). Then, using this plasmid pQAH1, E. coli JM109 was transformed. The transformant was cultured overnight at 28 ° C. in 2 ml of LB medium (containing 50 ⁇ g / ml ampicillin). After obtaining pQAH1 from this cell, Rhodococcus erythropolis L88 (Hokkaido System Science) was transformed with this plasmid. The transformant was cultured overnight at 28 ° C.
- 801-804 is a complex that catalyzes 2-aminoisobutyric acid hydroxylation reaction.
- PCR is performed under the following PCR conditions, and peg. PCR products 801, 802, and 803 were obtained.
- the PCR product was inserted into the vector pTipQC1 (Qiagen) treated with NcoI and HindIII. Then, using this plasmid pQAH-d804, E. coli was used. E. coli JM109 was transformed. The transformant was cultured overnight at 28 ° C. in 2 ml of LB medium (containing 50 ⁇ g / ml ampicillin). After obtaining pQAH-d804 from this cell, Rhodococcus erythropolis L88 (Hokkaido System Science) was transformed with this plasmid. The transformant was cultured overnight at 28 ° C.
- PCR is performed under the following PCR conditions, and peg. PCR products 801, 802, and 804 were obtained.
- PCR is performed under the following PCR conditions, and peg. PCR products of 803 and 804 were obtained.
- the PCR product was inserted into a vector pQE60 (Qiagen) treated with NcoI and HindIII. Then, using this plasmid pQEHyd, E. coli was used. E. coli JM109 was transformed. The transformant was cultured overnight at 28 ° C. in 2 ml of LB medium (containing 50 ⁇ g / ml ampicillin). Next, a part of the culture solution was added to 250 ml of TB medium (containing 50 ⁇ g / ml ampicillin), and cultured with shaking at 28 ° C.
- LB medium containing 50 ⁇ g / ml ampicillin
- IPTG was added to a concentration of 1 mM for the purpose of inducing protein expression.
- 2-aminoisobutyric acid was added as a reaction substrate to a concentration of 10 mM, and a shaking reaction was started.
- Rhodococcus bacteria was higher than that of Escherichia coli as the host of this reaction system.
- PCR is performed under the following PCR conditions, and peg. 800 PCR products were obtained.
- the PCR product was inserted into a vector pTipRT2 (Hokkaido System Science) treated with NdeI and HindIII using NEBuilder HiFi DNA Assembly Master Mix (New England England BioLabs). Then, using this plasmid pRAT1, E. coli was used. E. coli JM109 was transformed. The transformant was cultured overnight at 28 ° C. in 2 ml of LB medium (containing 50 ⁇ g / ml ampicillin). After obtaining pRAT1 from this cell, pQAH1 Rhodococcus erythropolis L88 produced in Example 3 was transformed with this plasmid.
- This transformant (pQAH1 / pRAT1 Rhodococcus erythropolis L88) was cultured overnight at 28 ° C. in 2 ml of LB medium (containing 5 ⁇ g / ml tetracycline and 20 ⁇ g / ml chloramphenicol). A part of the culture solution was added to a fresh 2 ml LB medium (5 ⁇ g / ml tetracycline, 20 ⁇ g / ml chloramphenicol included), and cultured with shaking at 28 ° C.
- thiostrepton was added to a concentration of 0.2 ⁇ g / ml for the purpose of inducing protein expression.
- 2-aminoisobutyric acid was added as a reaction substrate to a concentration of 10 mM, and the shaking reaction was started.
- optical purity of the produced ⁇ -methyl-D-serine was 93.5% ee.
- ⁇ Analysis conditions> ⁇ Measuring instrument: LCMS-2010A (Shimadzu Corporation) Column: Xbridge C18 column (5 ⁇ m: 2.1 ⁇ 150 mm) (Nippon Waters) -Column oven temperature: 40 ° C -Mobile phase A: 5% acetic acid-Mobile phase B: acetonitrile / methanol 90/10 ⁇ Flow rate: 0.25 ml / min ⁇ Gradient setting: 0 to 0.1 minutes 5% Mobile phase B, 0.1 to 30 minutes 5 to 35% Mobile phase B, 30 to 40 minutes 90% Mobile phase B, 40 to 50 minutes 5% mobile phase B MS conditions: Block temperature 200 ° C., Curved desolvation line temperature 250 ° C., Detector voltage 1.5 kV, nebulizing gas flow 1.51 / min 25 ⁇ l of reaction solution and 25 ⁇ l of 0.8% triethylamine acetonitrile solution are mixed, 50 ⁇ l The optical purity analysis was performed using a derivative
- Example 6 Evaluation of substrate specificity pQAH1 / pRAT1 Rhodococcus erythropolis L88 was cultured in LB medium in the same manner as in Example 5. After inducing protein expression with 0.2 ⁇ g / ml thiostrepton, 10 mM each of L-isovaline, D-isovaline, L-aminobutyrate, D-aminobutyrate was added along with 5% glucose. After the reaction for 26 hours, the reaction supernatant was analyzed by the LCMS analysis method shown in Example 1.
- PCR is performed under the following PCR conditions, and peg. PCR products of 803 and 804 were obtained.
- a part of the culture solution was added to 200 ml of TB medium (50 ⁇ g / ml ampicillin, 25 ⁇ g / ml containing chloramphenicol), and cultured with shaking at 20 ° C. After the culture turbidity reached 0.6 (absorption wavelength: 600 nm), IPTG was added to a concentration of 0.5 mM for the purpose of inducing protein expression. After culturing for 16 hours, the cells were collected by centrifugation and washed twice with 0.85% NaCl. The cells were suspended in 0.5 M NaCl, 30 mM imidazole, 20 mM HEPES (pH 8.0), and then sonicated.
- TB medium 50 ⁇ g / ml ampicillin, 25 ⁇ g / ml containing chloramphenicol
- IPTG was added to a concentration of 0.5 mM for the purpose of inducing protein expression. After culturing for 16 hours, the cells were collected by centrifugation and washe
- the above monooxygenase is peg. 803 and peg. It was estimated that each of 804 was composed of a heterotetramer structure as a whole monooxygenase.
- PCR is performed under the following PCR conditions, and peg. 801 PCR products were obtained.
- PCR product was inserted into a vector pQE80 (Qiagen) treated with BamHI and HindIII. Then, using this plasmid pQE-801, E. coli Rosetta 2 (DE3) was transformed. This transformant was cultured at 28 ° C. overnight in 2 ml of LB medium (containing 50 ⁇ g / ml ampicillin and 25 ⁇ g / ml chloramphenicol). A part of the culture solution was added to 200 ml of TB medium (50 ⁇ g / ml ampicillin, 25 ⁇ g / ml containing chloramphenicol), and cultured with shaking at 20 ° C.
- LB medium containing 50 ⁇ g / ml ampicillin and 25 ⁇ g / ml chloramphenicol
- IPTG IPTG was added to a concentration of 0.5 mM for the purpose of inducing protein expression. After culturing for 16 hours, the cells were collected by centrifugation and washed twice with 0.85% NaCl. The cells were suspended in 0.5 M NaCl, 30 mM imidazole, 20 mM HEPES (pH 8.0), and then sonicated. The centrifuged supernatant of this disrupted solution is introduced into HisTALON Superflow (1.6 ⁇ 2.5 cm) (Takara Bio) and eluted with 0.5 M NaCl, 30 mM imidazole, 150 mM HEPES (pH 8.0). Peg.
- the enzyme fraction containing 801 was collected. This enzyme fraction is concentrated by ultrafiltration, then introduced into MonoQ 10/100 GL column (1.0 ⁇ 10 cm) (GE Healthcare), and eluted with 1M NaCl, 20 mM Tris-HCl buffer (pH 7.4). Peg. 801 purified enzymes were obtained. 0.77 ⁇ g / ml of peg. 801 is added to a reaction solution containing 10-150 ⁇ M NADH or NADPH, 20-100 ⁇ M dichloroindophenol, 100 mM potassium phosphate buffer (pH 7.5). The enzyme activity of 801 was measured.
- the Km value in this reaction was measured and found to be 8.2 ⁇ M for NADH and 6.2 mM for NADPH. Therefore, peg. 801 was found to require NADH as a coenzyme.
- the present invention can be used in fields where a stable protein supply is required, for example, in the field of production of peptide pharmaceuticals.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
式(3)
αサブユニットが、以下の(a)~(d)からなる群より選択されるいずれかのタンパク質を含み、
βサブユニットが、以下の(e)~(h)からなる群より選択されるいずれかのタンパク質を含むことを特徴とする、〔1〕~〔4〕のいずれかに記載のモノオキシゲナーゼ:
(a)配列番号1に記載されるアミノ酸配列からなるタンパク質;
(b)配列番号1に記載されるアミノ酸配列において、1または数個のアミノ酸残基が置換、欠失、挿入および/または付加されたアミノ酸配列からなるタンパク質で、かつ、当該タンパク質を含むサブユニットがβサブユニットと複合体を形成したときにモノオキシゲナーゼ活性を有するタンパク質;
(c)配列番号1に記載されるアミノ酸配列と80%以上の相同性を有するアミノ酸配列からなるタンパク質で、かつ、当該タンパク質を含むサブユニットがβサブユニットと複合体を形成したときにモノオキシゲナーゼ活性を有するタンパク質;
(d)配列番号6に記載される塩基配列からなる遺伝子にコードされるタンパク質;
(e)配列番号2に記載されるアミノ酸配列からなるタンパク質;
(f)配列番号2に記載されるアミノ酸配列において、1または数個のアミノ酸残基が置換、欠失、挿入および/または付加されたアミノ酸配列からなるタンパク質で、かつ、当該タンパク質を含むサブユニットがαサブユニットと複合体を形成したときにモノオキシゲナーゼ活性を有するタンパク質;
(g)配列番号2に記載されるアミノ酸配列と80%以上の相同性を有するアミノ酸配列からなるタンパク質で、かつ、当該タンパク質を含むサブユニットがαサブユニットと複合体を形成したときにモノオキシゲナーゼ活性を有するタンパク質;
(h)配列番号7に記載される塩基配列からなる遺伝子にコードされるタンパク質。
(i)配列番号3に記載されるアミノ酸配列からなるタンパク質;
(j)配列番号3に記載されるアミノ酸配列において、1または数個のアミノ酸残基が置換、欠失、挿入および/または付加されたアミノ酸配列からなり、かつ、以下の(m)~(p)からなる群より選択されるいずれかのタンパク質と組み合わせたときに電子伝達活性を有するタンパク質;
(k)配列番号3に記載されるアミノ酸配列と80%以上の相同性を有するアミノ酸配列からなり、かつ、以下の(m)~(p)からなる群より選択されるいずれかのタンパク質と組み合わせたときに電子伝達活性を有するタンパク質;
(l)配列番号8に記載される塩基配列からなる遺伝子にコードされるタンパク質;
(m)配列番号4に記載されるアミノ酸配列からなるタンパク質;
(n)配列番号4に記載されるアミノ酸配列において、1または数個のアミノ酸残基が置換、欠失、挿入および/または付加されたアミノ酸配列からなり、かつ、上記の(i)~(l)からなる群より選択されるいずれかのタンパク質と組み合わせたときに電子伝達活性を有するタンパク質;
(o)配列番号4に記載されるアミノ酸配列と80%以上の相同性を有するアミノ酸配列からなり、かつ、上記の(i)~(l)からなる群より選択されるいずれかのタンパク質と組み合わせたときに電子伝達活性を有するタンパク質;
(p)配列番号9に記載される塩基配列からなる遺伝子にコードされるタンパク質。
さらに、以下に示す遺伝子を含む、〔10〕に記載の形質転換体:
(1)電子伝達系タンパク質をコードする遺伝子、および/または
(2)トランスポータータンパク質をコードする遺伝子。
以下の(m)~(p)からなる群より選択されるいずれかのタンパク質であることを特徴とする、〔11〕に記載の形質転換体:
(i)配列番号3に記載されるアミノ酸配列からなるタンパク質;
(j)配列番号3に記載されるアミノ酸配列において、1または数個のアミノ酸残基が置換、欠失、挿入および/または付加されたアミノ酸配列からなり、かつ、以下の(m)~(p)からなる群より選択されるいずれかのタンパク質と組み合わせたときに電子伝達活性を有するタンパク質;
(k)配列番号3に記載されるアミノ酸配列と80%以上の相同性を有するアミノ酸配列からなり、かつ、以下の(m)~(p)からなる群より選択されるいずれかのタンパク質と組み合わせたときに電子伝達活性を有するタンパク質;
(l)配列番号8に記載される塩基配列からなる遺伝子にコードされるタンパク質;
(m)配列番号4に記載されるアミノ酸配列からなるタンパク質;
(n)配列番号4に記載されるアミノ酸配列において、1または数個のアミノ酸残基が置換、欠失、挿入および/または付加されたアミノ酸配列からなり、かつ、上記の(i)~(l)からなる群より選択されるいずれかのタンパク質と組み合わせたときに電子伝達活性を有するタンパク質;
(o)配列番号4に記載されるアミノ酸配列と80%以上の相同性を有するアミノ酸配列からなり、かつ、上記の(i)~(l)からなる群より選択されるいずれかのタンパク質と組み合わせたときに電子伝達活性を有するタンパク質;
(p)配列番号9に記載される塩基配列からなる遺伝子にコードされるタンパク質。
(q)配列番号5に記載されるアミノ酸配列からなるタンパク質;
(r)配列番号5に記載されるアミノ酸配列において、1または数個のアミノ酸残基が置換、欠失、挿入および/または付加されたアミノ酸配列からなり、かつ、トランスポーター活性を有するタンパク質;
(s)配列番号5に記載されるアミノ酸配列と80%以上の相同性を有するアミノ酸配列からなり、かつ、トランスポーター活性を有するタンパク質;
(t)配列番号10に記載される塩基配列からなる遺伝子にコードされるタンパク質。
本発明の一実施形態において、少なくとも2種類のヘテロな(異なる)サブユニットにより構成されているモノオキシゲナーゼ(換言すれば、2種類以上の異なるサブユニットより構成されるヘテロモノオキシゲナーゼ)を提供する。
式(3)
(a)配列番号1に記載されるアミノ酸配列からなるタンパク質;
(b)配列番号1に記載されるアミノ酸配列において、1または数個のアミノ酸残基が置換、欠失、挿入および/または付加されたアミノ酸配列からなるタンパク質で、かつ、当該タンパク質を含むサブユニットがβサブユニットと複合体を形成したときにモノオキシゲナーゼ活性を有するタンパク質;
(c)配列番号1に記載されるアミノ酸配列と80%以上の相同性を有するアミノ酸配列からなるタンパク質で、かつ、当該タンパク質を含むサブユニットがβサブユニットと複合体を形成したときにモノオキシゲナーゼ活性を有するタンパク質;
(d)配列番号6に記載される塩基配列からなる遺伝子にコードされるタンパク質;
(e)配列番号2に記載されるアミノ酸配列からなるタンパク質;
(f)配列番号2に記載されるアミノ酸配列において、1または数個のアミノ酸残基が置換、欠失、挿入および/または付加されたアミノ酸配列からなるタンパク質で、かつ、当該タンパク質を含むサブユニットがαサブユニットと複合体を形成したときにモノオキシゲナーゼ活性を有するタンパク質;
(g)配列番号2に記載されるアミノ酸配列と80%以上の相同性を有するアミノ酸配列からなるタンパク質で、かつ、当該タンパク質を含むサブユニットがαサブユニットと複合体を形成したときにモノオキシゲナーゼ活性を有するタンパク質;
(h)配列番号7に記載される塩基配列からなる遺伝子にコードされるタンパク質。
本発明の一実施形態において、上記モノオキシゲナーゼと、電子伝達系タンパク質とを含む、β-ヒドロキシアミノ酸を製造するためのモノオキシゲナーゼ反応システムを提供する。
(i)配列番号3に記載されるアミノ酸配列からなるタンパク質;
(j)配列番号3に記載されるアミノ酸配列において、1または数個のアミノ酸残基が置換、欠失、挿入および/または付加されたアミノ酸配列からなり、かつ、以下の(m)~(p)からなる群より選択されるいずれかのタンパク質と組み合わせたときに電子伝達活性を有するタンパク質;
(k)配列番号3に記載されるアミノ酸配列と80%以上の相同性を有するアミノ酸配列からなり、かつ、以下の(m)~(p)からなる群より選択されるいずれかのタンパク質と組み合わせたときに電子伝達活性を有するタンパク質;
(l)配列番号8に記載される塩基配列からなる遺伝子にコードされるタンパク質;
(m)配列番号4に記載されるアミノ酸配列からなるタンパク質;
(n)配列番号4に記載されるアミノ酸配列において、1または数個のアミノ酸残基が置換、欠失、挿入および/または付加されたアミノ酸配列からなり、かつ、上記の(i)~(l)からなる群より選択されるいずれかのタンパク質と組み合わせたときに電子伝達活性を有するタンパク質;
(o)配列番号4に記載されるアミノ酸配列と80%以上の相同性を有するアミノ酸配列からなり、かつ、上記の(i)~(l)からなる群より選択されるいずれかのタンパク質と組み合わせたときに電子伝達活性を有するタンパク質;
(p)配列番号9に記載される塩基配列からなる遺伝子にコードされるタンパク質。
本発明の一実施形態において、上記タンパク質をコードするモノオキシゲナーゼ遺伝子を提供する。
本発明の一実施形態において、<3.遺伝子>の項に記載の遺伝子を含むベクターを提供する。本ベクターとしては、形質転換体作製のために宿主細胞内で、上記遺伝子を発現させるための発現ベクターのほか、組換えタンパク質の生産に用いるものも含まれる。
本発明の一実施形態において、<3.遺伝子>の項に記載の遺伝子または<4.ベクター>の項に記載の組換えベクターを含む形質転換体を提供する。ここで、「遺伝子またはベクターを含む」とは、公知の遺伝子工学的手法(遺伝子操作技術)により、対象細胞(宿主細胞)内に発現可能に導入されていることを意味する。また、上記「形質転換体」とは、細胞・組織・器官のみならず、生物個体を含む意味である。
(1)電子伝達系タンパク質をコードする遺伝子、および/または
(2)トランスポータータンパク質をコードする遺伝子。
(q)配列番号5に記載されるアミノ酸配列からなるタンパク質;
(r)配列番号5に記載されるアミノ酸配列において、1または数個のアミノ酸残基が置換、欠失、挿入および/または付加されたアミノ酸配列からなり、かつ、トランスポーター活性を有するタンパク質;
(s)配列番号5に記載されるアミノ酸配列と80%以上の相同性を有するアミノ酸配列からなり、かつ、トランスポーター活性を有するタンパク質;
(t)配列番号10に記載される塩基配列からなる遺伝子にコードされるタンパク質。
本発明の一実施形態において、<5.形質転換体>の項に記載の形質転換体を、α-アミノ酸またはα,α-2置換アミノ酸を含む培地中で培養する工程を含む、β‐ヒドロキシアミノ酸の製造方法を提供する。本実施形態におけるβ‐ヒドロキシアミノ酸の製造は、<5.形質転換体>の項に記載の形質転換体を用いるものであればよく、その他の具体的な構成、条件、材料、および使用設備等については、特段限定されない。
0.1% 2-アミノイソ酪酸、0.1% 塩化アンモニウム、0.1% リン酸2水素カリウム、0.1% リン酸水素2カリウム、0.03% 硫酸マグネシウム7水和物、0.01% Difco Yeast Nitogen Base w/o Amino Acids and Ammoniumu Sulfateで構成される2mlの集積用液体培地を用いて、自然界から採取した土壌サンプル各種を、28℃で5日間、振とう培養した(濃度はすべて(w/v)%で示す(以下、実施例全体に渡って同様))。微生物が生育してきた培養液を、2mlの新しい集積用液体培地に接種した。この操作を数回繰り返した後、同成分で調製した1.5% 寒天プレート培地にて、2-アミノイソ酪酸資化性微生物を単離した。単離した各微生物を再び2mlの集積用液体培地に播種し、28℃で5日間、振とう培養した。その後、8000gで10分間の遠心操作で集菌し、0.85%食塩水で2回洗浄した湿菌体を、以下の休止菌体反応に用いた。休止菌体反応は、10mM 2-アミノイソ酪酸、10mM グルコース、1mM アミノオキシ酢酸、5% 湿菌体を、50mM HEPESバッファー(pH7.5)中、300rpmで4時間振とうすることにより行った。
・測定機器:LCMS-2010A(島津製作所)
・カラム:Xbridge C18 カラム(5μm:2.1×150mm)(日本ウォーターズ)
・カラムオーブン温度:40℃
・移動相A:10mM 酢酸アンモニウム(pH5.0)
・移動相B:メタノール
・流速:0.3ml/分
・グラジエント設定:0~0.5分 0~1% 移動相B、0.5~18分 1~5% 移動相B、18~19分 5~9% 移動相B、19~29.5分 9~17% 移動相B、29.5~40分 17~60% 移動相B
・MS条件:ブロック温度 200℃、Curved desolvation line温度 250℃、Detector voltage 1.5kV、nebulizing gas flow 1.51/分
AccQ-Tag derivation kit(日本ウォーターズ)を用いて、分析溶液中のアミノ酸を誘導化した後に、LCMS分析に供した。
R. wratislaviensis C31-06株を、250mlの2-アミノイソ酪酸誘導液体培地(0.1% 2-アミノイソ酪酸、0.1% 塩化アンモニウム、0.1% リン酸2水素カリウム、0.1% リン酸水素2カリウム、0.03% 硫酸マグネシウム7水和物、0.01% Difco Yeast Nitogen Base w/o Amino Acids and Ammoniumu Sulfate)、または250mlの非誘導培地(2-アミノイソ酪酸誘導液体培地において、0.1% 2-アミノイソ酪酸の代わりに0.05%グルコースを使用)を用いて、28℃で38.5時間培養した(各々、n=3)。それぞれの培養菌体を、4℃、8000gで10分間の遠心分離で集菌し、7M尿素、2.0mMチオウレア、2%CHAPS、10mM ジチオスレイトール、1tablet/10ml プロテアーゼ阻害剤(Complete Mini,ロシュ)を含む50mM Tris-HCl(pH8.0)バッファーに懸濁した。0.10mmビーズを添加し、マルチビーズショッカーで菌体を破砕した後、4℃、20000gで15分間、遠心分離を行った。得られた遠心上清を細胞溶解液として使用した。200mM TEABバッファー(pH8.0)を最小量用いて沈殿物を洗浄し、細胞溶解液と合わせて、0.45μmのフィルターでろ過した。次いで、200mM TEABバッファーを用いてろ液を置換した。置換したろ液に9.5mM Tris(2-carboxyethyl)phosphineを添加し、55℃で60分間、処理した。その後、ヨードアセトアミドを17.9mMとなるように添加し、室温で30分間、処理した。最後に、2~4倍量の冷アセトンを添加し、-20℃で3時間、処理した。4℃、13000gで10分間の遠心分離により、タンパク質を回収した。残存アセトンは、37℃で2分間処理することにより、除去した。
・測定機器:Prominence Nano Flow System(島津製作所)
・カラム:Monolithic silica capillaryカラム (500cm長、0.1mm ID)(京都モノテック)
・カラムオーブン温度:40℃
・移動相A:0.1% ギ酸水溶液
・移動相B:0.1% ギ酸アセトニトリル
・流速:500ml/分
・グラジエント設定:0~600分 5~45% 移動相B
・MS条件:LTQ Velos linear ion trap mass spectrometer(Thermo Scientific)、2.3kVのESI voltage、LTQ Velos ion trap上のイオントランスファーチューブ温度=280℃
〔実施例3〕2-アミノイソ酪酸水酸化酵素および電子伝達系タンパク質の同定
実施例2で得られたProtein ID peg.801-804が2-アミノイソ酪酸水酸化反応を触媒する複合体であると予想されたことから、これらをコードする遺伝子の取得を試みた。
・鋳型:R. wratislaviensis C31-06株のゲノム (100ng/μl、1μl)
・ポリメラーゼ:PrimeSTAR Max Premix(2×)(タカラバイオ)(25μl)
・プライマー(pTipQC1_5’ Hyd):TGTTTAACTTTAAGAAGGAGATATACCATGGTTGCACCAACCTCGAA(配列番号11)(10μM、1μl)
・プライマー(pTipQC1_3’ Hyd):TGGTGATGGTGATGCTCGAGAGATCTACTAGAGATCGAGGACGAGCC(配列番号12)(10μM、1μl)
・増幅条件:98℃ 10秒、55℃ 5秒、72℃ 1分を30サイクル。
・測定機器:Shimadzu LC-VP(島津製作所)
・カラム:Xbridge C18 カラム(5μm:2.1×150mm)(日本ウォーターズ)
・カラムオーブン温度:40℃
・移動相A:Waters AccQ-Tag Eluent A
・移動相B:メタノール
・流速:0.3ml/分
・グラジエント設定:0~0.1分 0% 移動相B、0.1~0.5分 0~1% 移動相B、0.5~18分 1~5% 移動相B、18~19分 5~9% 移動相B、19~29.5分 9~17% 移動相B、29.5~40分 17~60% 移動相B、40~43分 60~0% 移動相B、43~55分 0% 移動相B
・検出:蛍光検出器(励起波長250nm 発光波長395nm)
AccQ-Tag derivation kit(日本ウォーターズ)を用いて、分析溶液中のアミノ酸を誘導化した後に、LC分析に供した。
〔4.1〕
Protein ID peg.801、802、803を発現する形質転換放線菌の構築を試みた。
・鋳型:R. wratislaviensis C31-06株のゲノム (100ng/μl、1μl)
・ポリメラーゼ:PrimeSTAR Max Premix(2×)(タカラバイオ)(25μl)
・プライマー(pTipQC1_5’ 803):TGTTTAACTTTAAGAAGGAGATATACCATGACCATCATCGAACACGG(配列番号13)(10μM、1μl)
・プライマー(pTipQC1_3’ Hyd):TGGTGATGGTGATGCTCGAGAGATCTACTAGAGATCGAGGACGAGCC(配列番号12)(10μM、1μl)
・増幅条件:98℃ 10秒、55℃ 5秒、72℃ 1分を30サイクル。
続いて、Protein ID peg.801、802、804を発現する形質転換放線菌の構築を試みた。
・鋳型:R. wratislaviensis C31-06株のゲノム (100ng/μl、1μl)
・ポリメラーゼ:PrimeSTAR Max Premix(2×)(タカラバイオ)(25μl)
・プライマー(pTipQC1_5’ Hyd):TGTTTAACTTTAAGAAGGAGATATACCATGGTTGCACCAACCTCGAA(配列番号11)(10μM、1μl)
・プライマー(joint802-4_3’):CGCTACCGATTACAAACTTGGACATTCTTAACCAACCTTTCCTGGGC(配列番号14)(10μM、1μl)
または
・プライマー(joint804-2_5’):CCCGAGCCCAGGAAAGGTTGGTTAAGAATGTCCAAGTTTGTAATCGG(配列番号15)(10μM、1μl)
・プライマー(pTipQC1_3’ Hyd):TGGTGATGGTGATGCTCGAGAGATCTACTAGAGATCGAGGACGAGCC(配列番号12)(10μM、1μl)
・増幅条件:98℃ 10秒、55℃ 5秒、72℃ 1分を30サイクル。
Protein ID peg.801-804を発現する形質転換大腸菌の構築を試みた。
・鋳型:R. wratislaviensis C31-06株のゲノム (100ng/μl、1μl)
・ポリメラーゼ:Tsk Gflex DNA Polymerase(タカラバイオ)(1.25ユニット/μl、1μl)
・プライマー(pQE60_5’ Hyd):GAATTCATTAAAGAGGAGAAATTAACCATGGTTGCACCAACCTCGAA(配列番号16)(10μM、1μl)
・プライマー(pQE60_3’ Hyd):CAACAGGAGTCCAAGCTCAGCTAATTACTAGAGATCGAGGACGAGCC(配列番号17)(10μM、1μl)
・増幅条件:98℃ 10秒、58℃ 15秒、68℃ 1分を30サイクル。
相同性検索の結果に基づき、実施例2で得られたProtein ID peg.800が、2-アミノイソ酪酸のトランスポーターであると予想されたことから、peg.800をコードする遺伝子の取得を試みた。
・鋳型:R. wratislaviensis C31-06株のゲノム(100ng/μl、1μl)
・ポリメラーゼ: PrimeSTAR Max Premix(2×)(タカラバイオ)(25μl)
・プライマー(pTipRT2_NdeI_5’ 800):GTTTAACTTTAAGAAGGAGATATACATATGACAGTGAATCATTCCCA(配列番号18)(10μM、1μl)
・プライマー(pTipRT2_HindIII_3’ 800):TGGTGATGGTGATGCTCGAGAGATCTATCAGATTCTGGGCTGCAGAA(配列番号19)(10μM、1μl)
・増幅条件:98℃ 10秒、55℃ 5秒、72℃ 1分を30サイクル。
・測定機器:LCMS-2010A(島津製作所)
・カラム:Xbridge C18 カラム(5μm:2.1×150mm)(日本ウォーターズ)
・カラムオーブン温度:40℃
・移動相A:5%酢酸
・移動相B:アセトニトリル/メタノール=90/10
・流速:0.25ml/分
・グラジエント設定:0~0.1分 5% 移動相B、0.1~30分 5~35% 移動相B、30~40分 90% 移動相B、40~50分 5% 移動相B
・MS条件:ブロック温度 200℃、Curved desolvation line温度 250℃、Detector voltage 1.5kV、nebulizing gas flow 1.51/分
25μlの反応溶液と25μlの0.8%トリエチルアミンアセトニトリル溶液とを混合し、50μlの2,3,4,6,-tetra-O-acetyl-β-D-glucopyranosyl isocyanateで誘導化したものを用いて、光学純度分析を行った。
実施例5と同様の方法により、pQAH1/pRAT1 Rhodococcus erythropolis L88をLB培地で培養した。0.2μg/mlのチオストレプトンでタンパク質の発現を誘導した後、10mMのL-イソバリン、D-イソバリン、L-アミノブチレート、D-アミノブチレートのそれぞれを、5% グルコースと共に添加した。26時間の反応後、実施例1に示すLCMS分析法にて、反応上清を分析した。
・鋳型:R. wratislaviensis C31-06株のゲノム (100ng/μl、1μl)
・ポリメラーゼ:PrimeSTAR Max Premix(2×)(タカラバイオ)(25μl)
・プライマー(pQE_804_5’):TCGCATCACCATCACCATCACGGATCCATGGTTGCACCAACCTCGAA(配列番号20)(10μM、1μl)
・プライマー(pQE_803_3’):CAACAGGAGTCCAAGCTCAGCTAATTATTAGTCCGCCTGATTCGTAA(配列番号21)(10μM、1μl)
・増幅条件:98℃ 10秒、55℃ 5秒、72℃ 1分を30サイクル。
Protein ID peg.801を発現する形質転換大腸菌の構築を試みた。
・鋳型:R. wratislaviensis C31-06株のゲノム (100ng/μl、1μl)
・ポリメラーゼ:PrimeSTAR Max Premix(2×)(タカラバイオ)(25μl)
・プライマー(pQE_801_5’):TCGCATCACCATCACCATCACGGATCCATGACCAATTCAGATAGTTC(配列番号22)(10μM、1μl)
・プライマー(pQE_801_3’):CAACAGGAGTCCAAGCTCAGCTAATTACTAGAGATCGAGGACGAGCC(配列番号23)(10μM、1μl)
・増幅条件:98℃ 10秒、55℃ 5秒、72℃ 1分を30サイクル。
Claims (17)
- 2種類のヘテロなサブユニットにより構成されていることを特徴とする、モノオキシゲナーゼ。
- α-アミノ酸またはα,α-2置換アミノ酸を、β-ヒドロキシアミノ酸に変換する反応を触媒することを特徴とする、請求項1に記載のモノオキシゲナーゼ。
- 上記2種類のヘテロなサブユニットを、それぞれαサブユニット、βサブユニットとすると、
αサブユニットが、以下の(a)~(d)からなる群より選択されるいずれかのタンパク質を含み、
βサブユニットが、以下の(e)~(h)からなる群より選択されるいずれかのタンパク質を含むことを特徴とする、請求項1~4のいずれか1項に記載のモノオキシゲナーゼ:
(a)配列番号1に記載されるアミノ酸配列からなるタンパク質;
(b)配列番号1に記載されるアミノ酸配列において、1または数個のアミノ酸残基が置換、欠失、挿入および/または付加されたアミノ酸配列からなるタンパク質で、かつ、当該タンパク質を含むサブユニットがβサブユニットと複合体を形成したときにモノオキシゲナーゼ活性を有するタンパク質;
(c)配列番号1に記載されるアミノ酸配列と80%以上の相同性を有するアミノ酸配列からなるタンパク質で、かつ、当該タンパク質を含むサブユニットがβサブユニットと複合体を形成したときにモノオキシゲナーゼ活性を有するタンパク質;
(d)配列番号6に記載される塩基配列からなる遺伝子にコードされるタンパク質;
(e)配列番号2に記載されるアミノ酸配列からなるタンパク質;
(f)配列番号2に記載されるアミノ酸配列において、1または数個のアミノ酸残基が置換、欠失、挿入および/または付加されたアミノ酸配列からなるタンパク質で、かつ、当該タンパク質を含むサブユニットがαサブユニットと複合体を形成したときにモノオキシゲナーゼ活性を有するタンパク質;
(g)配列番号2に記載されるアミノ酸配列と80%以上の相同性を有するアミノ酸配列からなるタンパク質で、かつ、当該タンパク質を含むサブユニットがαサブユニットと複合体を形成したときにモノオキシゲナーゼ活性を有するタンパク質;
(h)配列番号7に記載される塩基配列からなる遺伝子にコードされるタンパク質。 - 請求項1~5のいずれか1項に記載のモノオキシゲナーゼと、電子伝達系タンパク質とを含むことを特徴とする、β-ヒドロキシアミノ酸を製造するためのモノオキシゲナーゼ反応システム。
- 上記電子伝達系タンパク質が、以下の(i)~(l)からなる群より選択されるいずれかのタンパク質、および以下の(m)~(p)からなる群より選択されるいずれかのタンパク質であることを特徴とする、請求項6に記載のモノオキシゲナーゼ反応システム:
(i)配列番号3に記載されるアミノ酸配列からなるタンパク質;
(j)配列番号3に記載されるアミノ酸配列において、1または数個のアミノ酸残基が置換、欠失、挿入および/または付加されたアミノ酸配列からなり、かつ、以下の(m)~(p)からなる群より選択されるいずれかのタンパク質と組み合わせたときに電子伝達活性を有するタンパク質;
(k)配列番号3に記載されるアミノ酸配列と80%以上の相同性を有するアミノ酸配列からなり、かつ、以下の(m)~(p)からなる群より選択されるいずれかのタンパク質と組み合わせたときに電子伝達活性を有するタンパク質;
(l)配列番号8に記載される塩基配列からなる遺伝子にコードされるタンパク質;
(m)配列番号4に記載されるアミノ酸配列からなるタンパク質;
(n)配列番号4に記載されるアミノ酸配列において、1または数個のアミノ酸残基が置換、欠失、挿入および/または付加されたアミノ酸配列からなり、かつ、上記の(i)~(l)からなる群より選択されるいずれかのタンパク質と組み合わせたときに電子伝達活性を有するタンパク質;
(o)配列番号4に記載されるアミノ酸配列と80%以上の相同性を有するアミノ酸配列からなり、かつ、上記の(i)~(l)からなる群より選択されるいずれかのタンパク質と組み合わせたときに電子伝達活性を有するタンパク質;
(p)配列番号9に記載される塩基配列からなる遺伝子にコードされるタンパク質。 - 請求項1~5のいずれか1項に記載のタンパク質をコードするモノオキシゲナーゼ遺伝子。
- 請求項8に記載の遺伝子を含むことを特徴とする組換えベクター。
- 請求項8に記載の遺伝子または請求項9に記載の組換えベクターを含むことを特徴とする形質転換体。
- さらに、以下に示す遺伝子を含む、請求項10に記載の形質転換体:
(1)電子伝達系タンパク質をコードする遺伝子、および/または
(2)トランスポータータンパク質をコードする遺伝子。 - 上記電子伝達系タンパク質が、以下の(i)~(l)からなる群より選択されるいずれかのタンパク質、および
以下の(m)~(p)からなる群より選択されるいずれかのタンパク質であることを特徴とする、請求項11に記載の形質転換体:
(i)配列番号3に記載されるアミノ酸配列からなるタンパク質;
(j)配列番号3に記載されるアミノ酸配列において、1または数個のアミノ酸残基が置換、欠失、挿入および/または付加されたアミノ酸配列からなり、かつ、以下の(m)~(p)からなる群より選択されるいずれかのタンパク質と組み合わせたときに電子伝達活性を有するタンパク質;
(k)配列番号3に記載されるアミノ酸配列と80%以上の相同性を有するアミノ酸配列からなり、かつ、以下の(m)~(p)からなる群より選択されるいずれかのタンパク質と組み合わせたときに電子伝達活性を有するタンパク質;
(l)配列番号8に記載される塩基配列からなる遺伝子にコードされるタンパク質;
(m)配列番号4に記載されるアミノ酸配列からなるタンパク質;
(n)配列番号4に記載されるアミノ酸配列において、1または数個のアミノ酸残基が置換、欠失、挿入および/または付加されたアミノ酸配列からなり、かつ、上記の(i)~(l)からなる群より選択されるいずれかのタンパク質と組み合わせたときに電子伝達活性を有するタンパク質;
(o)配列番号4に記載されるアミノ酸配列と80%以上の相同性を有するアミノ酸配列からなり、かつ、上記の(i)~(l)からなる群より選択されるいずれかのタンパク質と組み合わせたときに電子伝達活性を有するタンパク質;
(p)配列番号9に記載される塩基配列からなる遺伝子にコードされるタンパク質。 - 上記トランスポータータンパク質が、以下の(q)~(t)からなる群より選択されるいずれかのタンパク質であることを特徴とする、請求項11または12に記載の形質転換体:
(q)配列番号5に記載されるアミノ酸配列からなるタンパク質;
(r)配列番号5に記載されるアミノ酸配列において、1または数個のアミノ酸残基が置換、欠失、挿入および/または付加されたアミノ酸配列からなり、かつ、トランスポーター活性を有するタンパク質;
(s)配列番号5に記載されるアミノ酸配列と80%以上の相同性を有するアミノ酸配列からなり、かつ、トランスポーター活性を有するタンパク質;
(t)配列番号10に記載される塩基配列からなる遺伝子にコードされるタンパク質。 - 上記形質転換体が、ロドコッカス(Rhodococcus)属細菌であることを特徴とする、請求項10~13のいずれか1項に記載の形質転換体。
- 請求項10~14のいずれか1項に記載の形質転換体を、α-アミノ酸またはα,α-2置換アミノ酸を含む培地中で培養する工程を含むことを特徴とする、β‐ヒドロキシアミノ酸の製造方法。
- 上記形質転換体に含まれる請求項8に記載の遺伝子が、ロドコッカス(Rhodococcus)属由来であることを特徴とする、請求項15に記載の製造方法。
- ロドコッカス ラティスラビエンシス(Rhodococcus wratislaviensis) C31-06株(受託番号:NITE BP-02370)。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18776149.9A EP3604505A4 (en) | 2017-03-31 | 2018-03-29 | NOVEL MONOOXYGENASE AND USE THEREOF |
CN201880022361.2A CN110832073A (zh) | 2017-03-31 | 2018-03-29 | 新型单加氧酶及其用途 |
JP2019510160A JPWO2018181774A1 (ja) | 2017-03-31 | 2018-03-29 | 新規モノオキシゲナーゼおよびその利用 |
US16/584,734 US20200010814A1 (en) | 2017-03-31 | 2019-09-26 | Novel monooxygenase and utilization thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017071338 | 2017-03-31 | ||
JP2017-071338 | 2017-03-31 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/584,734 Continuation-In-Part US20200010814A1 (en) | 2017-03-31 | 2019-09-26 | Novel monooxygenase and utilization thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018181774A1 true WO2018181774A1 (ja) | 2018-10-04 |
Family
ID=63676152
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2018/013363 WO2018181774A1 (ja) | 2017-03-31 | 2018-03-29 | 新規モノオキシゲナーゼおよびその利用 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20200010814A1 (ja) |
EP (1) | EP3604505A4 (ja) |
JP (1) | JPWO2018181774A1 (ja) |
CN (1) | CN110832073A (ja) |
WO (1) | WO2018181774A1 (ja) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010029610A1 (ja) * | 2008-09-09 | 2010-03-18 | サントリーホールディングス株式会社 | ハイブリッドアルファーグルコシドトランスポーター |
JP2011084564A (ja) * | 1998-09-03 | 2011-04-28 | Japan Science & Technology Agency | アミノ酸輸送蛋白及びその遺伝子 |
JP4877227B2 (ja) | 2005-05-20 | 2012-02-15 | 味の素株式会社 | L−セリン誘導体の製造方法およびこれに用いる酵素 |
JP2012529274A (ja) * | 2009-06-08 | 2012-11-22 | イェンネワイン バイオテクノロジー ゲーエムベーハー | ヒトミルクオリゴ糖の合成 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1811029A4 (en) * | 2004-11-10 | 2008-03-12 | Marine Biotech Inst Co Ltd | PROCESS FOR ISOLATING THE P450 GENE |
CN1329506C (zh) * | 2005-09-06 | 2007-08-01 | 清华大学 | 一种具有颗粒状甲烷单加氧酶活性的重组菌及其应用 |
JP5246639B2 (ja) * | 2006-09-28 | 2013-07-24 | 味の素株式会社 | 4−ヒドロキシ−l−イソロイシンの製造法 |
-
2018
- 2018-03-29 JP JP2019510160A patent/JPWO2018181774A1/ja active Pending
- 2018-03-29 CN CN201880022361.2A patent/CN110832073A/zh active Pending
- 2018-03-29 EP EP18776149.9A patent/EP3604505A4/en not_active Withdrawn
- 2018-03-29 WO PCT/JP2018/013363 patent/WO2018181774A1/ja active Application Filing
-
2019
- 2019-09-26 US US16/584,734 patent/US20200010814A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011084564A (ja) * | 1998-09-03 | 2011-04-28 | Japan Science & Technology Agency | アミノ酸輸送蛋白及びその遺伝子 |
JP4877227B2 (ja) | 2005-05-20 | 2012-02-15 | 味の素株式会社 | L−セリン誘導体の製造方法およびこれに用いる酵素 |
WO2010029610A1 (ja) * | 2008-09-09 | 2010-03-18 | サントリーホールディングス株式会社 | ハイブリッドアルファーグルコシドトランスポーター |
JP2012529274A (ja) * | 2009-06-08 | 2012-11-22 | イェンネワイン バイオテクノロジー ゲーエムベーハー | ヒトミルクオリゴ糖の合成 |
Non-Patent Citations (13)
Title |
---|
ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 410 |
ALTSCHUL ET AL., NUCLEIC ACIDS RES., vol. 25, 1997, pages 3389 - 3402 |
CLAUDIO MAPELLI ET AL., J. MED. CHEM., vol. 52, 2009, pages 7788 - 7799 |
DAVIS ET AL., BASIC METHODS IN MOLECULAR BIOLOGY, 1986 |
FANG, T. ET AL.: "Purification and characterization of salicylate 5-hydroxylase, a three-component monooxygenase from Ralstonia sp. strain U2", APPLIED MICROBIOLOGY AND BIOTECHNOLOGY,, vol. 98, no. 2, 2014, pages 671 - 679, XP035328418 * |
JACKSON, B. G. ET AL.: "Enantioselective Syntheses of 1-Carbacephalosporins from Chemoenzymically Derived β-Hydroxy-α-Amino Acids: Applications to the Total Synthesis of Carbacephem Antibiotic Loracarbef", TETRAHEDRON, vol. 56, no. 31, 28 July 2000 (2000-07-28), pages 5667 - 5677, XP004213797 * |
KIMURA, T. ET AL.: "Enzymatic Synthesis of β-Hydroxy-α-amino Acids Based on Recombinant d- and l-Threonine Aldolases", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 119, no. 49, 1997, pages 11734 - 11742, XP055558740 * |
MUELLER, L. A. ET AL.: "Characterization of a tyrosinase from Amanita muscaria involved in betalain biosynthesis", PHYTOCHEMISTRY, vol. 42, no. 6, August 1996 (1996-08-01), pages 1511 - 1515, XP055558731 * |
NARITA, M. ET AL.: "A natural variant of bovine dopamine β-monooxygenase with phenylalanine as residue 208: purification and characterization of the variant homo- and heterotetramers of (F208) 4 and (F208) 2 (L208) 2", FEBS LETTERS, vol. 396, no. 2-3, November 1996 (1996-11-01), pages 208 - 212, XP055558735 * |
PROC. NATL. ACAD. SCI. USA, vol. 87, 1990, pages 2264 - 2268 |
PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 5873 - 5877 |
See also references of EP3604505A4 |
TAKASHI OOI ET AL., J. AM. CHEM. SOC., vol. 125, 2003, pages 5139 - 5151 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2018181774A1 (ja) | 2020-02-20 |
EP3604505A1 (en) | 2020-02-05 |
US20200010814A1 (en) | 2020-01-09 |
CN110832073A (zh) | 2020-02-21 |
EP3604505A4 (en) | 2020-02-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zelasko et al. | Optimizations to achieve high-level expression of cytochrome P450 proteins using Escherichia coli expression systems | |
JP7292442B2 (ja) | 改変アミノアシルtRNA合成酵素およびその用途 | |
JP5590649B2 (ja) | 変異体ピロリジル−tRNA合成酵素及びこれを用いる非天然アミノ酸組み込みタンパク質の製造方法 | |
US20150376581A1 (en) | T7 rna polymerase variants and methods of using the same | |
JP5419220B2 (ja) | エステル結合を含む非天然タンパク質の製造方法 | |
US8883459B2 (en) | Process for production of cis-4-hydroxy-L-proline | |
Gourinchas et al. | A synthetic biology approach for the transformation of L-α-amino acids to the corresponding enantiopure (R)-or (S)-α-hydroxy acids | |
JP4936290B2 (ja) | 非天然型アミノ酸を組み込んだタンパク質の製造方法 | |
US20220348974A1 (en) | Biotin synthases for efficient production of biotin | |
CN108998462A (zh) | 含锰离子重组蛋白的大肠杆菌表达系统及其应用方法 | |
CN110607335B (zh) | 一种烟酰胺腺嘌呤二核苷酸类化合物生物合成方法 | |
WO2018181774A1 (ja) | 新規モノオキシゲナーゼおよびその利用 | |
US20190330672A1 (en) | Highly efficient and tunable system for the incorporation of unnatural amino acids into proteins in escherichia coli | |
WO2021219124A1 (zh) | 经修饰的苏氨酸转醛酶及其应用 | |
WO2016068218A1 (ja) | デヒドロゲナーゼ化した変異酵素及びその用途 | |
CN112831532A (zh) | 一种酶促合成d-亮氨酸的方法 | |
JP6735461B2 (ja) | 組換え大腸菌及びその利用 | |
JP7289836B2 (ja) | プロリンヒドロキシラーゼ、ならびにそれに伴う使用、方法および生成物 | |
JP5697327B2 (ja) | シス−ヒドロキシ−l−プロリンの製造方法 | |
US20220267742A1 (en) | Nadph-regeneration system based on monomeric isocitrate dehydrogenase and use thereof | |
KR102067475B1 (ko) | 3-히드록시프로피온산 반응 전사인자를 이용한 3-하이드록시프로피온산 선택성 유전자회로 및 이를 이용한 3-히드록시프로피온산 생산 균주의 스크리닝 방법 | |
JP6996714B2 (ja) | N-サクシニル-ヒドロキシ-d-アミノ酸及び/又はヒドロキシ-d-アミノ酸の製造方法 | |
KR101617371B1 (ko) | 메타게놈 유래 신규 베이어 빌리거 모노옥시게나아제 BVMOgm1 | |
KR101619864B1 (ko) | 메타게놈 유래 신규 베이어 빌리거 모노옥시게나아제 BVMOsm1 | |
KR20230162685A (ko) | 아실 CoA 화합물 환원 활성을 갖는 재조합 폴리펩티드 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18776149 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2019510160 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2018776149 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2018776149 Country of ref document: EP Effective date: 20191031 |